MedTrace Logo

Pilot Study of Neoantigen Peptides for the Treatment of Neoplasms

NCT04509167 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-03-06

No results posted yet for this study

Summary

This research is a pilot clinical trial using personalized neoantigen peptide vaccines with an adjuvant (Montanide ISA-51 VG), in patients with different types of cancer

Conditions

  • Neoplasms

Interventions

BIOLOGICAL

Neoantigen Peptides

Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 8 weeks.

Sponsors & Collaborators

  • Instituto de Medicina Regenerativa

    lead INDUSTRY

Principal Investigators

  • Jesus Perez, MD · Instituto de Medicina Regenerativa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-10
Primary Completion
2022-06-24
Completion
2022-06-24

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04509167 on ClinicalTrials.gov